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1. Introduction 
First, the chapter summarizes the specialties, which are appeared in the red (medical) 
biotechnology in the occurrent risks/uncertainties point of view. Then it draws attention to the 
fact that part of the literature about risks/uncertainties (for example in the environmental 
literature) serve as a broad basis for the analysis and evaluation of uncertainty. This seems also 
useful for the examinations of the uncertainties in the medical biotechnology, but as far as we 
know, it is not applied. Finally, the third part of the chapter follows a new analysis and it 
introduces that there is an uncertainty dilemma in the research of the medical biotechnology, 
which can be reduced, but can not be eliminated. 
2. Biotechnological innovations and trends 
Biotechnology is spreading rapidly in the pharmaceutical, environmental protection, 
agricultural, and other industrial environments. The number of molecules produced by 
biotechnological methods is growing rapidly, thanks to new methods and an almost 
exponentially increasing knowledge base. 
The appearance of novelties is very fast. There is a significant technological leap, from time 
to time. These radical innovations are aimed at solving complex problems by implementing 
and integrating new technologies. Radical innovations that lead to disruptive technological 
development in biotechnology based industry and especially in red biotechnology are 
usually result of long term research. These innovations provide a broad platform for a new 
regime in technology, from time to time [1]. At the same time, disruptive innovation is not 
necessarily radical. Small innovations can also have great disruptive economical influence, 
provided they are introduced in a new milieu. Just think about the turning to containers in 
oversee ship cargos, for example, when containers had already been much earlier utilised in 
other areas of transport.  
Companies were forced to cooperate due to the high risk associated with biotechnology, the 
complexity of strategic management rules and the unusually high amount of needed funds. 
First of all, the necessary monetary tools are available only at the largest companies. Second, 
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the necessary competencies are often missing with smaller companies. For example, a 
smaller company, a market leader in R&D, most probably does not have the necessary 
experience either of the capability needed to clinical testing or production. Cooperation is 
necessary to fill these gaps. With this sharing of different sorts of risks will be realised. 
These risks - actually non-calculable uncertainties several times, or at least the calculations 
can not be serve as reliable planning tools - may be technology, market, regulatory or 
competition related. The competition related one reflects on the segments of all the other 
risks, since the rapid development of China, South Korea and India. The only comparative 
advantages can only be quality and knowledge the traditional pharma producing countries 
have. But precisely these are areas where China and India are developing rapidly, while 
maintaining the seemingly natural price advantage. Europe and the USA can only compete 
with these products if they do not count on price advantage, but on therapeutic advantage. 
This means producing a newer, better molecule, first of all. However this larger added 
intellectual value brings larger risks, uncertainties on behalf of technological, market and 
registration. These tendencies are also catalysts of cooperation, for cooperation means some 
risk sharing.  
It is precisely these different, but interrelated risks that make pharmaceutical biotechnology 
complex. To successfully manage complex processes and instability necessitates 
cooperation. Instabilities are cross-linked. They can even strengthen or weaken each other. 
An example of mutual strengthening of uncertainty is the technological uncertainty of 
producing a new molecule, and the registration and legalization which follow. Registration 
gives the same molecule an added economical value and can, if it is registered already, 
decrease market instability, since it can become a market leader, a so called “blockbuster”1, 
with multi-million dollar yearly turnover.  
Drug manufacture is a multinational phenomenon, with an active global trade in 
intermediates (specialty chemicals), active pharmaceutical ingredients, and finished 
products. R&D, by contrast, is much more geographically concentrated; the bulk of all R&D 
expenditure occurs in the United States, a handful of European countries, and Japan. The 
pharmaceutical value chain encompasses many activities, ranging from basic scientific 
research to marketing and distribution. Innovation in the industry is tightly linked to basic 
biomedical science, and many companies participate actively in basic scientific research that 
generates new fundamental knowledge, data, and methods. 
Drug discovery includes basic science and research on disease physiology, identification 
and validation of “druggable targets” in the body where therapeutic molecules may affect 
disease processes, identification and optimization of drug candidates, and preclinical 
testing. The development phase of research focuses on testing in humans, from the first 
small-scale trials directed at establishing basic physiological data in healthy volunteers 
through to large-scale trials on patients having the disease, which are designed to provide 
data on safety and efficacy to support applications for regulatory approval of the drug. 
Following marketing approval, research often continues to develop improved formulations 
of the product and to establish safety and efficacy in treatment of additional diseases or 
patient populations. Reflecting extraordinary advances in biology and biochemistry since 
the 1970s, the industry has become progressively more science intensive, relying closely on 
                                                 
1 A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. 
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fundamental advances in physiology, biochemistry, and molecular biology rather than 
“brute force” application of large-scale resources. If anything, this process has accelerated 
over the past decade as the industry has focused on complex and systemic diseases such as 
cancer, autoimmune diseases, and psychiatric conditions. Particularly in drug discovery, 
industrial and publicly funded research efforts are deeply intertwined. 
Rapid growth in technological capabilities in low-cost emerging economies is presenting 
new opportunities and challenges for pharmaceutical companies. Some geographic 
redistribution of R&D activity does appear to be taking place. On the one hand, companies 
located in countries such as India and China are performing more in-house R&D oriented 
toward developing new drugs, rather than reverse-engineering existing products or 
improving production efficiency. On the other hand, reflecting the general trend of the 
industry toward greater specialization and external sourcing of R&D services, OECD-based 
companies are beginning to look to low-cost countries as suppliers of contract research 
services, and growing numbers of clinical trials are being conducted in emerging economies. 
India and China are the two countries most frequently mentioned in this regard; however, 
by some indicators significant growth in activity also appears to be taking place in some 
Eastern European countries, Argentina, Brazil, Taiwan, South Africa, and Israel. Over the 
past decade, the biotechnology industry has been the focus of increasing academic and 
policy interest as a potential source of regional and national economic development [2] [3]. 
Historical development of biotechnology can be divided into several large eras [4]: 
 The period started with the first conscientious use of biotechnology. This process 
started in the second half of the XIX century (about 1865), when Pasteur discovered that 
fermentation is caused by microorganisms. After understanding the essence of this 
process through microbiology, its industrial application became feasible. The beer and 
alcohol industries developed, vinegar and lactic acid production began. The production 
of ethanol, butanol, acetone, glycerin, citric acid etc. through fermentation began.  
 The discovery of antibiotics provided the momentum for the second great leap around 
1940. The productivity of microorganisms was increased by biological, genetic and 
biochemical methods (mutation, selection). Building on these opportunities and the 
rapid development of fermentation techniques, the result was a veritable technological 
revolution. The most important results were the large scale production technologies of 
antibiotics, amino acids and enzymes. 
 The next phase started in the first half of the 1970-s. The essence of this new 
biotechnology is that by altering the heritable material of living beings, through a 
conscious and planned manner, results in the development of new characteristics. 
Through the use of recombinant DNA and cell fusion, humans begun to alter the 
characteristics and functions of living organisms to suit their needs. 
 The fourth era is linked to the first commercial sale of human insulin (1982). This is the 
first member of the rDNA pharmaceutical products, meaning the large scale 
distribution of the products of the previous era. Thus growth gained even more 
momentum.  
 The fifth era can be marked by the latest great innovation, on one hand, the cloning of 
animals by the use of a cell nucleus, the creation of “Dolly” (1997) and later other cloned 
animals and on the other, the completion of the “Human Genome Project” (2000). 
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To make expectations essentially belongs to the development of new technologies. Many 
people see biotechnology as the industry of decisive strategic importance, following 
informatics at the start of the XXI century. According to optimistic forecasts, by the middle 
of the next decade, the pharmaceutical and biotechnology industries will become the 
leading industrial branches in the world, surpassing information technology and 
telecommunication. (In this article we will only concentrate on red (medical) biotechnology.) 
Expectations regularly realise some cyclic dynamic. One can argue that elements in that 
dynamic follow each other by necessity. Following the first hope even deep disillusion can 
be the next step as it was with the ecommerce bubble around the turn of the century. While 
with biotechnology the hope phase is still very strong, with time delay, unexpectedly raising 
costs, etc. in comparison to optimisticforecasts, the hope phase can partially turn into 
disillusion urging to change the earlier expected enthusiasm into more “rational” thinking.  
 
Fig. 1. [1] based on [7]: Ratio of newly registered pharmaceuticals: chemical and biotech 
entities.  
The EU considers the development of the biotech industry in view of the pharmaceutical 
industry exceptionally important and is rather optimistic about its future and the role the 
EU can play in it. This means strengthening collaboration between the two sectors [5]. 
Biotechnology plays an increasingly important role in pharmaceutical development, by 
preventing the onset of and curing previously un-curable diseases through the 
implementation of new diagnostic methods and treatments. Pharmaceuticals produced 
through biotech methods, such as proteins, antibodies, enzymes comprised 25% of 
pharmaceutical sales in 2003, already [6]. But most of the pharmaceuticals currently 
undergoing clinical trials are biotechnological in origin. The percentage of pharmaceuticals 
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produced using biotechnological methods, is growing rapidly. Of all registered small 
molecules, significantly more are produced by biotechnological methods, than by synthetic 
methods. (Figure 1.)  
These were all changes that radically altered the perspectives and tasks of biotechnology. 
Main directions of research were shifted, and the map of biotechnology was rearranged by 
economic factors as well. Therefore these are definitely disruptive innovations. Figure 2. 
shows growth of biotechnological knowledge, plotted against a timeline:  
 
Fig. 2. [the authors]. Changes of the knowledge level in biotechnology  
Usually, there is a complex, multidimensional, non-linearly correlated uncertainty 
surrounding disruptive, especially radical innovations, the solution of which often requires 
cross linked steps. It is important to state, that in terms of management, in opposition to 
small innovations, the management of radical innovations includes the ability to navigate in 
sight of unforeseeable events [1].  
Biotechnology and pharmaceutical companies 
Medical biotechnology is realised by two main types of companies. They are either large 
companies drawing on a long history in the given field and developing into more and more 
innovative biotechnology users, such as large pharmaceutical companies (“big pharma”). 
Or, modern biotechnological companies emerge, which the previously stated large 
companies purchase knowledge, projects or services from. Mainly the large companies 
control the biotechnology industry with regard to revenue. However this does not lead to 
strict adherence to traditions and the conservation of states of power. This is because, in 
terms of knowledge and the number of innovative projects, altogether small biotech 
companies have the comparative advantage.  
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Many biotech companies were founded in the 80-s. (e.g. Idec, SAFC Pharma, Enzyme Bio-
Systems,Novagen). First they sought to become completely vertically integrated companies, 
encompassing everything from R&D to production and sales. They realised “closed 
innovation”, only. Gradually, these companies brought new trends in their innovation 
strategies. At first the companies lacked two things that kept them from reaching their goals: 
the lack of funds, and experienced managers. However, these two things are essential (in 
addition to technology) for a company to grow from a spin-off enterprise to a large 
pharmaceutical company. The classic pharmaceutical companies, being on the top that time, 
already possessed these resources. Thus some of them purchased biotech companies while 
others however were not open to biotechnology in terms of investment and cooperation [8].  
The volume and complexity of biotech and pharmaceutical projects grew in relation to the 
amount of available information and acquired knowledge in an environment of steadily 
growing needs for new knowledge. This placed further emphasis on cooperation, the 
sharing of costs and risks of producing new R&D results, because an industry of high risk-
high benefit type emerged. This led to problems, but opportunities as well. Concerning the 
problems it was asked: Who will finance the costs of research? Will investors think that the 
industry is too risky? Naturally the significance of professional investors and specific 
tenders? increased with this.  
Companies were forced to cooperate due to the high risk associated with biotechnology, the 
complexity of strategic management rules and the unusually high amount of needed funds. 
First of all, the necessary monetary tools are available only at the largest companies. Second, 
the necessary competencies are often missing with smaller companies. For example, a 
smaller company, a market leader in R&D, does not have the necessary experience either of 
the capability needed to clinical testing or production. Cooperation is necessary to fill these 
gaps. With this sharing of different sorts of risks will be realised. These risks, actually non-
calculable uncertainties several times, may be technology, market, regulatory or competition 
related. The latter reflects on the segments of all the other risks, since the rapid development 
of China, South Korea and India. The only advantages can only be quality and knowledge 
for the traditional pharma producing countries. But precisely these are areas where China 
and India are developing rapidly, while maintaining the seemingly natural price advantage. 
Europe and the USA can only compete with these products if they do not count on price 
advantage, but on therapeutic advantage. This means producing a newer, better molecule, 
first of all. However this larger added intellectual value brings larger risks on behalf of 
technological, market and registration. These tendencies are also catalysts of cooperation.  
It is precisely these different, yet interrelated risks that make pharmaceutical biotechnology 
complex. To successfully manage complex processes and instability necessitates 
cooperation. Instabilities are cross-linked, they can even strengthen or weaken each other. 
An example of mutual strengthening is the technological uncertainty of producing a new 
molecule, and the registration and legalization which follow. Registration gives the same 
molecule an added economical value and can, if it is registered already, decrease market 
instability, since it can become a market leader, a so called “blockbuster” with multi-million 
dollar yearly turnover.  
Thus instabilities constitute a kind of synergic system. Instabilities are difficult to predict 
individually, their interrelations are even more so.  
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Fig. 3. [the authors]: a typical time-schedule of a new biotech identity 
Necessity of cooperation can be explained from another point of view as well (figure 3). 
Validity period of a patent is 20 years from the date of application, which, in case of 
pharmaceuticals can be extended by at most 5 years (SPC). According to Figure 3, the 
product generally appears on the market 13-15 years after the patent application. With the 
end of the patent period, one must also count with the appearance of generic and biosimilar 
products.2 Thus there is, at most 10, but more often only 5 years to cover the entire costs of 
R&D and clinical costs and make some revenue. Thus everyone seeks to make the time 
needed for R&D as short as possible. One method could be some sort of open innovation, 
which supports cooperation and outsourcing instead of solving everything in-house. /On 
“open innovation” you find more details in [9] and 10] /. There are numerous factors which 
make a part of the R&D earlier fully integrated in the vertical control target of outsourcing. 
To shorten the needed time to find a molecule and make it a drug, the steeply growing costs 
of keeping all the needed expertise within the firm, the decreasing costs of reaching the 
needed expertise outside, together the transaction costs arguments and the abundance of 
expertise outside are all for giving advantage to trust R&D tasks to outsiders who are 
already experts in the given field. This method definitely saves time and possibly costs as 
well and systematically open access to better solutions than those available in a “closed 
innovation” method.  
                                                 
2 A generic drug (generic drugs, short: generics) is a drug which is produced and distributed without 
patent protection. The generic drug may still have a patent on the formulation but not on the active 
ingredient. 
Biosimilars or follow-on biologics are terms used to describe officially approved new versions of 
innovator biopharmaceutical products, following patent expiry. 
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The consequences of uncertainty 
Not all of the multinational drug companies had enough courage to apply the newest 
discoveries of biotechnology from their own budget. Obviously they regarded to these 
projects as they are too risky and for multinational and successful companies they didn’t 
provide enough motivation to jeopardize their convenient state. But smaller enterprises, 
spin-off companies and biotechnological organizations must had to apply the new and more 
risky technology, which is based on new paradigm, because this was the only competitive 
edge for them against the big companies. 
Until recently biotechnological companies have limited themselves to the early phase of the 
research and they sold their products, ideas and research results to drug companies. These 
biotechnological companies were quite small, and they had no possibilities to develop their 
own product as drog, only the “knowledge-import” were really achievable for them. Most 
of them became bankrupt, did not become successful, only some of them stayed alive after 
the initial phase. 
Multinational drug companies often bought ready molecules from small biotechnology 
enterprises before or after the clinical phase II. With these purchase they could reduce their 
non-calculable risk attached to the uncertainties of R&D – although it stayed significant in 
this phase, too – but at the same time it caused success for small biotechnology enterprises. 
As a result new types of organizations appeared: e.g. contract manufacturing organizations 
(CMO) sites (contractual plant), contract research organizations CRO organizations 
(contractual research site), advisory and supply companies. This process can also interpret, 
which says that organizations share their risks similarly to their work and revenue. 
So risks can be reduced thanks to cooperation and when risks are non-calculable, the 
precaution provides the other possible solution. The above mentioned risk reducing 
mechanisms suggest to apply the “open innovation” method, which can be read in details in 
the final document. 
The four elements of the required framework highlight the key resources and dynamics 
associated with the emergence and sustainability of leading clusters in all segments of the 
biotechnology industry. First, as mentioned earlier, the development of biotechnology 
innovation requires access to specialized inputs, including researchers, risk capital, 
biological materials, and even intellectual property. By and large, accessing these resources 
is most easily accomplished within a regional context, rather than across long distances or 
political boundaries. For example, the development of the agricultural biotechnology cluster 
surrounding St. Louis depended on the ability of companies such as Monsanto to draw 
upon and reinforce the significant expertise and research capabilities of Washington 
University in St. Louis. 
Second, a key driver of effective clustering in the biotechnology sector seems to be 
competition among locally based biotechnology companies. These companies compete on 
the basis of attracting talent, publishing high-quality scientific research, and attracting 
investment and interest from venture capitalists and downstream commercial partners, 
many of whom are located outside the cluster. This is perhaps most apparent in some of the 
clusters associated with health-oriented biotechnology; for example, the Massachusetts 
biotechnology cluster includes more than 400 different firms, 235 of which are developing 
therapeutic drugs [11].  
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Third, most leading biotechnology clusters are located not only near sources of high-quality 
basic research but also around areas with significant capacity in clinical innovation. For 
example, the pressures on the Massachusetts biotechnology cluster arise as much from the 
presence of demanding clinicians in the leading hospitals as from that of specialized 
genetics researchers. Similarly, the medical device cluster in Minneapolis is pushed by 
demanding consumers at the Mayo Clinic and related institutions, and industrial 
biotechnology innovation in Scandanavia depends in part on demanding customers in the 
chemical industry [12]. 
Finally, the biotechnology cluster depends on the presence of related and supporting 
industries, most notably an active venture capital industry to supply managerial expertise, 
risk capital, and relationship experience with downstream partners as well as key pieces of 
infrastructure (e.g., biological resource centers, specialized seed banks and agricultural 
research stations, specialized equipment and tools). Each of these factors encourages the 
investment of sunken assets and the development of specialized capabilities that reinforce 
the strength and ultimately the international competitiveness of that cluster environment. 
While the United States remains the largest single national home for biotechnology activity, 
it is useful to note that the EU actually accounts for a greater number of companies than the 
United States. [13]. Along with the earlier employment statistics, this suggests that 
individual EU biotechnology companies have fewer employees (on average) than their U.S. 
counterparts. Simply put, this means that the scale of operations for a typical EU 
biotechnology firm is smaller than that of a biotechnology firm in the United States. 
Furthermore, the European biotechnology companies seem to grow more slowly than their 
U.S. counterparts. By and large, young European firms are often overtaken by international 
competitors and even some of the oldest European biotechnology companies have been 
acquired by U.S. companies that have better access to financial and commercialization 
resources [8]. As in the employment statistics, this concentration of small companies seems 
to reflect the international distribution of employment activities. 
This central insight—an increase in the number of regional innovation clusters, rather than a 
simple dispersion of biotechnology activity—holds several important implications for (1) 
evaluating the global biotechnology industry going forward and (2) developing effective 
policy to ensure continued U.S. leadership in this area. 
First, some analysis suggests that the impact of globalization on biotechnology innovation 
seems to be different than that of traditional manufacturing sectors, such as the automobile 
industry or the IT sector. Specifically, the globalization of other industries reflects the 
increasing availability of low-cost locations to conduct activities that previously had been 
done in the United States. In contrast, the globalization of biotechnology reflects a “catching 
up” process by a small number of regions around the world that seek to compete head-to-
head with leading regions in the United States. 
Second, it is important to account for the range of activities now included within the 
biotechnology industry, including diverse applications in the life sciences, agriculture, and 
industry. Although most discussion focuses on life sciences—which remains the largest 
single segment of biotechnology in terms of employment, enterprises, investment, and 
patenting—the globalization of biotechnology is occurring most rapidly in industrial 
www.intechopen.com
 
Management of Technological Innovation in Developing and Developed Countries 
 
94
applications. Moreover, although the United States continues its historical advantage in 
agricultural applications, this may be due to political resistance in Europe and other regions 
rather than the presence of strong agglomeration economies within the United States. For 
example, the presence of extremely strong clusters with a high level of entrepreneurship 
that characterizes life sciences biotechnology seems to be a bit less salient for agricultural 
applications. The presence of multiple industrial segments—each of which is associated 
with distinct locational dynamics—raises the possibility that, even as individual clusters 
become more important within each application area, the total number of global clusters 
may increase with the range of applications. 
Third, at least in terms of the available data, the United States maintains a very strong, even 
dominant, position within biotechnology. While some conceptual frameworks (e.g., the 
convergence effect) would suggest that early leadership by the United States would have 
been followed by a more even global distribution of biotechnology innovation, the “gap” 
between the United States and the rest of the world has remained relatively constant over 
the past decade or so. Indeed, itis likely that the United States has a historic opportunity to 
establish a long-term position as a global hub for biotechnology innovation, particularly in 
the life sciences and agricultural areas. In contrast to traditional debates about outsourcing, 
it is possible that increased global activity in biotechnology can complement rather than 
substitute for U.S. investment, employment, and innovation. 
Finally, our analysis highlights the small size (in terms of absolute levels of employment) of 
the biotechnology industry. While industries such as IT may plausibly be associated with a 
large impact on the total workforces of individual states and regions, total employment in 
biotechnology is very small, although associated with very high average wages. The simple 
fact is that, if the biotechnology industry remains at roughly the same scale that it has 
achieved over the past decade or so, it is unlikely to be a major driver of employment 
patterns and overall job growth, either in the United States or abroad. 
Trends in the Pharmaceutical industry3 
In terms of individual pharmaceutical trends, there are many cited novel commercial 
models and the rising importance of emerging markets as the most promising. Further 
consolidation through Mergers, Acquisitions and alliances and partnerships made it a close 
third. Difficult market access and reimbursement were named as the biggest risks, along 
with pricing pressure and general cost containment. Novel commercial models have been an 
industry issue for a while. Not only have new stakeholders, such as payors and patients, 
gained influence. On a different note, many managers believe that by rethinking traditional 
models, corporations could improve their image. 
The rising importance of emerging markets is reflected by a number of developments. For 
example, in 2008, GlaxoSmithKline established an Emerging Markets region and appointed 
its President to the Corporate Executive Team. Contrary to mature markets, the middle class 
in such regions has increased its purchasing power. Furthermore, the public provision of 
healthcare is improving. Yet some stumbling blocks remain, such as the issue of 
liberalization in Russia or the need for better protection of intellectual property in India. 
However, in summary, there is no doubt that emerging markets will provide a key growth 
                                                 
3 We rely in this chaper on the [14] heavily. 
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engine in the midto long-term. In the meantime, the BRIC countries allow the industry to 
learn in a "non-traditional", much more consumer-driven environment. 
The challenges ahead4  
Market access and reimbursement have emerged as top management issues. According to 
our survey, generating demand with physicians is no longer sufficient. This can be traced 
back to the increasing hurdles related to reimbursement. Hence, many managers expect that 
the trend, not to launch products in certain markets, will accelerate – as could already be 
witnessed in the UK, Germany and France. 
As with reimbursement, general cost containment has also resulted in significant pricing 
pressure across most markets. A major driver of this development is the discounts which are 
granted to payors. Moreover, due to fragmented budgets and decision-making, total costs 
are not relevant enough: It is the price of the product which counts. 
Most executives concur that R&D productivity remains a key challenge. Some are even 
convinced that this is the underlying issue for all of the industry's problems. For one, costs 
are on a steady rise. Yet, due to poor clinical trial results and higher regulatory hurdles – 
which have increased costs by 50% and more – the number of approvals cannot keep pace. 
"The industry needs to apply a model which is less fragmented and much more 
entrepreneurial", said one top manager. The issue of insufficient intellectual property 
protection earned mixed reactions. While some managers believe that it could challenge the 
existence of the entire industry, others are not as pessimistic. Some pointed out that, should 
patent protection fail, R&D expenses could be reduced by two thirds. Others see the matter 
as a call for action: "The industry should stop fighting for patent protection and learn to 
create protected market situations using different instruments, such as brands or customer 
loyalty." 
The industry is reviewing its commercial model. While corporations are driven by the wish 
to better cope with changing customer structure and become more cost-effective, they are 
simultaneously investing in services. At this point in time, however, this is seen as an effort 
to maintain customer access and loyalty, rather than as a contribution to revenue and profit. 
Even in today's challenging economic environment, the pharmaceutical industry can still be 
considered an industry with good long-term prospects. Expanding aging populations, 
increased wealth in emerging markets and unmet medical needs, accompanied by rapid 
technological progress, are fueling the demand for innovative drugs – and will continue to 
do so in the future. 
Product innovation and patents – formerly the driving forces behind the industry – have lost 
momentum. After years of high growth for shareholders in the 1980s and 90s, significant 
value has been destroyed since the turn of the century. The old blockbuster business model 
has lost its appeal. The pipeline has dried up and the number of commercially viable 
candidates is down. Companies show limited willingness to have a large share of their sales 
depend on just a few products. Health systems are challenging the highmargin business 
                                                 
4 We rely in this chaper on the [15] heavily. 
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model of the industry, primarily by questioning the value contribution of "pseudo-
innovations" and "me-too" products.  
Fierce competition from generics and a growing focus on price in tender business. The first 
step for executives in pharmaceutical companies is to review which therapeutic areas (TAs) 
they are currently active in and decide whether these are really the most promising ones. 
What are the TAs with the highest potential in terms of revenue growth and profitability in 
the next five years: 
 Oncology 
 CNS 
 Cardiovascular 
 Vaccines 
 Diabetes 
 Immunology 
For many years the typical product manufactured by the pharmaceutical industry was the 
pill or capsule containing small molecules surrounded by galenic technology. This has 
changed dramatically in recent years and more changes are on the way. We asked 
participants in the survey what type of physical pharma product they thought would gain 
most in importance in the coming five years. Here's what they said: 
- Biologicals will be the strongest growth drivers in the next five years (49% of 
respondents) 
- Combinations of pharmaceuticals and diagnostics were ranked second (30%) 
- Small molecules came third (9%) – a dramatic drop in the ranking from previous years 
- Cell-based therapeutics came a close fourth (7%) 
This shift in product types is expected to have a major impact on the pharmaceutical value 
chain. Thus, pharmaceutical companies seeking approval for expensive biologicals will need 
to clearly demonstrate the additional benefit of their drugs in order to ensure 
reimbursement. Indeed, in the survey, 74% of respondents considered reimbursement and 
market access the biggest challenges faced in the pharma value chain. Demographic change 
and technological advance are driving the demand for pharmaceutical products. But most 
pharmaceutical companies operate in markets which are not liberalized. In such markets, 
prices are not the result of supply and demand but of restrictive governmental healthcare 
systems that limit market growth. In light of the financial crisis and the resulting large fiscal 
debts, growth is set to slow even further. We therefore asked the participants in our survey 
to name the financial source that they thought would fuel the growth of the R&D-based 
pharma business model in the coming five years.  
The majority of respondents in the survey (78%) said that the first step would be to 
improve the personal or "soft" skills of their employees. Specialist expertise is also seen as 
major challenge by respondents working in the area of R&D. One such respondent 
commented as follows: "It is not only about those soft skills. You need the top people with 
the top specialist know-how for those TAs you want to play in." To achieve cultural 
excellence, pharma executives intend to focus on three levers: (1) gaining access to the 
best talent; (2) fostering entrepreneurship rather than bureaucracy; and (3) focusing on the 
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scientific culture in R&D, incentivizing employees accordingly. We will discuss each of 
these levers in turn below. 
3. Risks and uncertainties 
Calculating risk needs on the most basic level knowledge of the issues, the variables, 
damages or benefits, and knowledge of the occurrence of their probability. Andrew Stirling 
[16] elegantly demonstrates how with lessening of knowledge of the variables, that can 
occur as impossibility of setting just one model of the issues, because of value differences in 
indication what the important problem to choose is, and parallel with this, lessening 
knowledge of probabilities separates different areas of uncertainty.  
Figure 4 shows the risk sharing process. By their nature, completely new biotechnological 
projects, aiming at radical innovation, originally fall into the “suicide box”. They are 
characterized by high market and technological uncertainty. In a given situation, a small 
biotech company, since it has no other choice, working out the right technology, sells it to 
the larger pharmaceutical company. From the point of view of the big company, the 
technological uncertainty is reduced considerably, since it is purchasing a technology that 
has been proven to work. (The technology is over the proof of the concept phase) The 
market uncertainty remains now to solve, which can be assessed and estimated by the 
purchaser. Another extreme case is when a small innovative company tries to become a 
supplier for one of the large market players. Trying to meet its needs, perhaps even 
relocating closer to the purchaser, is thus reducing market uncertainty for both parties. Thus 
the reason for cooperation is to decrease at least one, but preferably both (marked by dashed 
arrow) uncertainties. By sharing the associated risks, the organizations will not be able to 
reach the small innovation level, as this is not the goal of the cooperation. But at least they 
can decrease risk somewhat.  
The not always appropriate knowledge of the events causes an enormous problem for 
biotechnology. For example in drug manufacturing with genetically modified organisms, in 
comparison to traditional pharmaceuticals new problems appear, such as the social and 
environmental acceptance of the technology that can be doubtful. This generalized the 
judgement of the work with recombinant organisms, independently of the fact that the 
organisms are isolated when they are in use. However those “classic” events, which have 
influence on the behaviour of the pharmaceutical manufacturing, for example the cartel of 
the competitors and the status of the industrial property, have played a role yet. The 
appearance of biogeneric or biosimilar molecules, which generate further uncertainty (n-
dimension uncertainty) in the field of regulation and licensing, is a new and not predicted 
problem. All this indicates that the actors in the red biotechnology are often unable to set 
risk calculations, first because unpredictable variables emerge, crop up.  
The probabilities are the other problem. There are fields, where the probabilities can be 
estimated relatively easily (e.g. industrial property, technician feasibility), but elsewhere it is 
a really hard work (e.g. modification of regulation, variability of marketability, price or 
supply and demand). The latter cases cannot be generalized from the classical examples of 
the pharmaceutical or chemical industry, because they are biotech-specific. On the whole, 
there are also probabilities which can be regarded as unknowns. The most difficult thing is 
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to take into consideration the hazard of the unknown processes before decision. So in the 
case of a radical biotechnological innovation we can talk about ignorance, the field of the 
real surprise in the figure. 
 
Fig. 4. The risk sharing process, based on[16] (modified by the author) 
Hence we can regard that sooner or later in the field of the drastic decrease of the 
knowledge we can not only talk about uncertainty but its extreme case, ignorance, because 
we don’t know or cannot know about neither the probability of the occurrence, nor the 
existence of the forthcoming events [17]. 
Breakthrough, radical innovations are created under circumstances which lead to genuine 
surprise. They necessarily imply essential previous ignorance, and result in genuine 
surprise. To different extents, this is the definition of radical innovations. That is the reason 
why managing radical innovation, the uncertainty and the unknown, the sphere of 
ignorance, has a consequence. That is that some sort of trial and error approach is a key 
issue, so any recognition of some, even very weak paternisation, regularity can be enormous 
comparative advantage. With this we acquire some plausible knowledge about a part of the 
“previously unknowable” while taking certain interrelations into account. It can be stated 
that during the evaluation of an uncertain situation partly the “I know that I know” 
problems should be handled. In this case a deterministic, at least a probability based answer 
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can be provided for. Other problems are of an “I know that I don't know” nature (I know the 
phenomenon but I don't know the possibility of the occurrence). In this case we can provide 
plausible answers. The third type is the “I don't know that I don't know” problem, meaning 
ignorance, already a challenge that both even events and effects are unknown. These are 
extreme situations e.g. when extreme security requirements are to be realised or 
outstandingly high profit is searched for. In permanently turbulent environments these 
questions become the natural questions. [18] 
Two types of problems emerge in very uncertain situations. First, we literally do not know 
what can happen (for example by the synergistic effects of known factors and what can the 
effect be) and second, we do not know the frequency of what happens either. It is most 
important to see that the main problem with these types of issues is not the calculability 
with prognostic aim. The problem is the lack of knowledge what can occur at all, the so 
called lack of ability of modelling.  
In terms of biotechnology, uncertainty in the progressing realization of some innovation can 
be understood more as “ignorance” or “real surprise” for a while. With the accelerating 
development of biotech industry the domain of “we don’t know what we don’t know”, the 
range of insufficiently known events and distributions, ‘original surprises’ is becoming 
increasingly important, in most cases also accented by irreversibility [19]. Fuzzy sets 
considerations can only be part of the solution for these types of issues. At their border 
“ignorance” is impossible not to take into account if there are reasons that the turbulence is 
very high.  
The lack of the possibility to make reliable risk calculations poses a problem. For example, 
when looking at the production of pharmaceuticals through genetically modified organisms, 
producers have been faced by problems such of the societal acceptance of the questionable 
health and environmental consequences of the technology. These concerns result in an 
overall negative judgment of all technology using recombinant organisms, regardless of 
their isolation during use. At the same time, “classic” events influencing pharmaceutical 
production still play a role, such as the merging and cooperation of concurrent companies in 
the background, as well as the state of industrial rights protection. A new and non-
foreseeable problem is the appearance of biogeneric / biosimilar molecules, which generate 
further uncertainty in the fields of regulation and registration (n-th dimension uncertainty). 
Based on this we can ascertain that in case of the drastic reduction of knowledge, sooner or 
later we can begin talking about lack of knowledge, ignorance instead of uncertainty, since 
we do not have, in certain cases, we cannot have any information regarding the events to 
come, not just the frequency of their occurrence [20]. The trivial consequence for action is 
than that it is wortwhile to prepare to accommodate, as a very basic element of the strategy 
of firms, to new situations occurring as consequences of genuine surprises.  
But to provide approapriate knowledge base for any risky situation, notwithstanding that 
they are calculable or not, is not enough to take into account risk/uncertainty facts, only. 
When dealing with the role of uncertainty for decision making mostly it is too much told 
about the risk facts, the analytical level. To make decision, action conclusions leads to 
empirical fallacy, a misbelief that facts alone can lead to decisions. But decision making 
unavoidably includes risk evaluation too. It is unfortunate that the risk assessment literature 
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neglects this layer.Actually, it is a hidden assumption that everybody naturally makes the 
same evaluation of the same facts but this is a simple error. Following Schwartz and 
Thompson, and utilizing ideas from lectures of Imre Hronszky and the PhD Dissertation of 
Ágnes Fésüs we shortly demonstrate what with risk evaluation the issue is. Actually at risk 
evaluation for basic types of evaluating perspectives can be utilized. The Figure 5 below 
demonstrates them.  
Types of nature represented by different potential curves accepted by the four different 
types of agents in society, according to Schwarz and Thompson: 
 
Fig. 5. Four different types of agents in society, by Schwarz and Thompson based on [17] 
On risks and uncertainties 
The assessment of risks (uncertainties) in the technological development is becoming an 
increasingly difficult task to solve. This is especially true in a rapidly changing turbulent 
environment, where environment and its knowledge changes from day to day, where in 
addition to small ones, radical innovations are typical as well. Understanding the necessary 
parameters is becoming more and more uncertain, thus also becoming limited. There is a 
huge literature on technological uncertainty just as there is on risks of financial issues.  
Two types of problems emerge in very uncertain situations. First, we literally do not know 
what can happen (for example by the synergistic effects of known factors and what can the 
effect be) and second, we do not know the frequency of what happens either. It is most 
important to see that the main problem with these types of issues is not the calculability 
with prognostic aim. The problem is the lack of knowledge what can occur at all, the so 
called lack of ability of modelling.  
The classical scientific assessment of uncertainty is the quantitative risk assessment (qRA). If 
you know the damaging events and their frequencies you certainly can make prognostic 
calculations, too. QRA has a quite long success story in modernity. But, for its reductive 
nature, that we have to know these very basic preconditions, it is with ignorance (‘deep 
uncertainty’) hopelessly challenged in strongly turbulent issues and with basic lacks in 
knowledge. These types of problems will be more and more often. 
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Understanding uncertainty in modernity has developed as a progressing capability of 
calculation of risks, the quantitative risk assessment (qRA). As its essential it is calculation of 
the probabilities of occurrence of some known set of events and multiplying these 
probabilities with the possible damages the set of events may cause. This way the qRA aims 
at the best possible prediction of risks. This approach includes into the (probabilistic) 
deterministic planning and command and control regulatory approach. All these issues, 
qRA, deterministic planning, command and control approaches require the existence of 
quite strong preconditions (as, concerning qRA I indicated above). These strong 
preconditions can up to a grade be weakened. For example fuzzy set techniques can be 
included concerning the estimations of events.  
It is important to see at least in outline how uncertainty of events and likelihoods and the 
plurality of the values as a societal fact for democracies have challenged the modernist 
approach to uncertainty. Andy Stirling, in line with some other authors, elegantly 
summarizes the basic problematic of quantitative risk approach as providing for a 
reductive-aggregative way to interpreting uncertainty [20]. One can speak about reductivity 
in the meaning that the classical risk research reduces its interest in calculable risk. This 
could be done, concerning the production dimension, in time of mass production. Then long 
periods were stable and made the prognostic effort rather successful. We can make rational 
suppositions on the basic preconditions of risk calculation in such periods. Additionally, a 
lot of efforts have been made by practitioners in risk research to find methods to 
successfully assess situations when quantitative risk calculation ceases to work exactly. This 
applies both for making conjectures about the existence of events as well as their 
probabilities.  
It is just a platitude to say that knowledge in any real case is incomplete in most decision 
situations. Important is what sorts of incompleteness are or/and are to be recognized. From 
the quantitative risk perspective, to be able to function, we should be able to identify the 
events that should be taken into account and should be able to attribute values to 
probabilities at least as subjective guesses. But one can also consider a further case when this 
does not work with either the events or the probabilities. Instead the earlier cases even 
strong ‘surprises’ may occur. History helps us to learn on empirical base that these sorts of 
cases, issues and effects of ‘unknown unknowns’ are real cases. These can occur without any 
human interaction or as results of them. It is possible to argue that high complexity of the 
issues provides for frequent occurrence of ‘surprises’. All the radical innovations are in their 
realisation process for a while ‘surprises’, too.  
On the precautionary approach 
All this is connected to some recognition of the nature of uncertainty of the processes and 
the appropriate management efforts. The new permanent and decisive challenges are 
decision making and action under the pressure of comprehensive and irreparable 
information uncertainty in a world of ‘ontological uncertainties’, as this is typically 
formulated.  
Risk management based on quantitative risk assessment does not help much in these issues. 
The reason is that both the needed type of assessment and the controllability of the process 
too are realisable in a limited way only. Risk assessment has to draw back to the second line, 
to the efforts made for isolation and control of special issues. But this should not open the 
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way to nihilism. Instead, some sort of precautionary approach is possible to unify as we try 
to emphasize the commitment of the actor both for utilising suddenly appearing chances 
and avoiding hazards. While risk calculation, the extension of the calculative rationality 
attitude to uncertain situations, in principle promised the certainty of exact calculation of the 
one best solution (in an ideal world where neither the unavoidable multiplicity of values, 
the ‘combinatorial complexity’ neither real complexity disturbs) rational management of 
complex processes has to be satisfied with calculations unavoidably leaving essential place 
for uncertainty. This is where value choices have their structural place. With this we already 
want to call attention to the issue that it is reasonable to think of a continuum of approaches, 
made of different combinations of courage and drawing back. This continuum of behaviour 
reflects the variability of human agents’ relation to the uncertainty as a world of chance and 
hazard.  
Modernity first had success with mathematically handling deterministic issues. Then it went 
further and had immense success in handling probabilistically deterministic issues. As its 
pair in management caution and prevention may be seen as key categories developed by 
modernity in relation to mastering negative effects. This is mastering by and preventing 
based on (in principle exact) understanding of the probability of causal mechanisms. In this 
latter case it is risk that comprises the relation of modernity to uncertainty: uncertainty can 
in principle be bounded in exact calculus. As for exchange there is no place for surprise in 
issues where quantitative risk assessment is valid, as Frank Knight sharply recognized in 
1916. This is to set against a ‘post’-modern ‘world’ in which interactions and ‘deep 
uncertainty’ assessments get the supreme position. The realised rationality by modernity is 
calculation of isolated issues as exactly as it can be done, with the result of possible exact 
prediction of the effects. Its action part is to come to term with the outcomes the 
probabilities of which are calculated. This rationality of more and more exact calculation is 
the basis for acting through deterministically planning that is based on evaluating the 
realisability of probabilistically predicted positive and avoidability of the negative effects. It 
is oriented toward exactness in quantity. That means that the methodological effort can 
concentrate on identifying the degree of risk. Concerning the future, this open space of 
unknown, risk calculation commits itself to understand future through extrapolation based 
on some continuity. Estimated uncertainties in the future are compared with the known 
risks recently and these are hypothetically extended to trends into the future. (With this 
there is a, not always conscientious reductive presumption made on the type and ‘measure’ 
of novelty. Because the induction problem is unsolvable in principle trend extrapolation has 
to be decisionistically accepted. It will or won’t be rejected. At some point we do not reject 
anymore as Bernstein [20] correctly recognized the extrapolative guess as measure for what 
can be novel in the future. There are two different basic types of practices to realise this non-
rejection. We may make it because it is acceptable for modelling or for practical reasons in 
the real practice.)  
Risks appear this way as if they were quasi-natural variables, objective, repeatable, and 
measurable in standardised situations. But we know that risks are social-natural variables, 
damages are damages in relation to some values, only. So, even when they seem to be quasi-
natural variables, a justified multiplicity of risks can be identified around the same issue, 
expressing the (often conflicting) relations of interested groups to the risky issue. This is the 
mentioned ambiguity of the valuing relation. Life is obviously more complex than any of the 
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leading ideas on which actions can be based on their purified forms. Modernity also 
experienced that values are irreducibly multiple in democratic societies and that 
uncertainties around the data and the models definitely hinder the unambiguity 
quantitative exactness risk management in its ideal form requires. The unceasable value 
plurality, as characteristic for the manifoldness of the social processes and a democratic 
society together is a strong challenge to classical risk assessment. It challenges at least its 
claimed punctual exactness, its capability to provide for any unique ‘objective standard’ for 
decision making. Risk assessment is unavoidably based on some ‘subjective’ framing. From 
the endless many perspectives one will be chosen to serve for realising a qRA process. One 
has further to see that risk is not only social-natural variable because it expresses a special 
evaluative relation (damage) to some object but risk is also constructed in reality: one can 
rightfully, strictly speak of quantitative risks of an action in standardized systems, only. So, 
either the situation is really standardised as far as possible in the real practice or is identified 
so as it really would be standardised.  
4. Conlusion 
Pharmaceuticals is a highly globalized industry, dominated by multinational companies that 
engage in significant business activity in many countries and whose products are 
distributed and marketed worldwide. Historically, the industry has been dominated by 
vertically integrated firms performing almost all of the activities in the value chain by the 
firm itself, from basic research through to sales and marketing. They realised some sort of 
“closed innovation”, as Henry Chesbrough introduced the term. [12]  
In recent decades the industry has undergone dramatic structural changes, with the rise of 
the biotechnology sector, substantial growth in demand driven by demographics, 
substitution away from other therapeutic modalities such as surgery, and increased 
competition from globally active generic manufacturers 
Pharmaceutical biotechnology, just like other dynamically growing branches of industry, 
has been very rapidly changing. Disruptive innovations arise from time to time. Since this is 
a very high risk - high benefit industry, and already R&D phases often require several 
hundred millions of dollars, the participants seek to minimize and share risk, more precisely 
the uncertainties, not always calculable as quantitative risks.  
In case of biotechnology the assessment of risks (uncertainties) in the technological 
development is becoming an increasingly difficult task to solve. This is especially true in a 
rapidly changing turbulent societal, economic, political, ideological environment, where that 
environment and knowledge of it changes from day to day, where, in addition to small 
ones, radical innovations are not seldom but typical as well. Understanding the necessary 
parameters is becoming more and more uncertain, thus also becoming profoundly limited, 
just as with the whole dynamics.  
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